Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Chise Profile picture
@sailorrooscout
Apr 16, 2021 • 5 tweets • 1 min read • Read on X
Please keep in mind variant B.1.167 out of India is still considered a variant of interest, not a variant of concern. B.1.167 lineage isolates are actually common in India and while it carries mutations E484Q and L452R, it does not carry any deletion mutations we see in current
variants of concern. Lastly, this variant was present in India last year, and while media highlights the presence of it in the UK as recent, it’s first occurrence in the UK dates back to February 22nd. The claims that it bypasses T-cell immunity are NOT currently substantiated.
The most important thing as always is to get vaccinated and control its spread. Let’s stay focused. Current variants of concern are: B.1.351, P.1, B.1.1.7, and B.1.427/B.1.429.
Also, please don’t even try the “she doesn’t take this seriously.” I wouldn’t be doing what I do if I didn’t. The difference is I value facts over fear.
Also, yes. I meant B.1.617. Really need that edit button. I notice these things too late.

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Chise

Chise Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

Chise Profile picture
Oct 28, 2024
THIS IS HUGE! An HIV PrEP drug candidate in the form of a twice-yearly subcutaneous injection has been shown to reduce HIV infections by 96% in a SECOND late-stage Phase III trial. Lenacapavir was 99.9% effective at preventing HIV in MORE THAN 2,000 participants.🧵⬇️
Source:
• gilead.com/news/news-deta…Image
These results come from the PURPOSE 2 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous Lenacapavir in individuals aged 16 years or older. Lenacapavir, which is a capsid inhibitor, is already approved by the FDA under the brand name Sunlenca for use alongside other
Read 13 tweets
Chise Profile picture
Oct 24, 2024
So, not COVID related BUT, this is REALLY exciting news. Phase I/II data shows Moderna’s Norovirus vaccine candidate mRNA-1403, has shown early signs of efficacy AND elicited robust serum HBGA-blocking antibody responses against ALL THREE NoV genotypes. Let’s talk about that!🧵⬇️
At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomized, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections.
As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden. Symptoms include vomiting and diarrhoea, which can be severely dehydrating, and the risk of severe outcomes from NoV is greatest in young children and older
Read 16 tweets
Chise Profile picture
Oct 21, 2024
THIS IS HUGE! Researchers at JHU have developed an experimental drug called RK-33, that in preclinical studies has shown promise in treating breast cancer with bone metastases. RK-33 eliminated the metastases AND prevented further cancer spread. Let’s talk about that!🧵⬇️
The research has been published in Cancer Letters. Yes, it is PEER-REVIEWED.
• sciencedirect.com/science/articl…Key Takeaways: •RK-33 targets DDX3, an RNA helicase elevated in cancer cells, to inhibit breast cancer bone metastasis. •In mouse models, RK-33 eliminated bone metastases and prevented further cancer spread without significant adverse effects. •The study suggests RK-33 as a promising treatment for breast cancer bone metastasis, urging further research into its broader applications.
In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis). RK-33 was previously shown to help treat other types of cancer and viral illnesses.
Read 14 tweets
Chise Profile picture
Oct 17, 2024
THIS IS HUGE! Researchers at Lancaster University have developed RI-AG03, a peptide inhibitor, that in preclinical studies PREVENTED the build-up of harmful Tau proteins in the brain, which are believed to be a key driver of Alzheimer’s disease. Let’s talk about that! 🧵⬇️
The research has been published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Yes, it is PEER-REVIEWED.
•~ alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…What You Need to Know ⬇️ •Scientists have developed a new drug that targets two key regions of the tau protein, a major contributor to Alzheimer’s disease. •The drug, a peptide inhibitor called RI-AG03, successfully prevented the build-up of toxic tau proteins in both laboratory and fruit fly studies. •Although further research is necessary, including clinical trials in humans, this research contributes to the advancement of more effective therapies for neurodegenerative diseases. •There are two main “hotspots” on the tau protein, where fibril clumping occurs. In this new study, research...
Tau proteins are essential for maintaining the structure and function of neurons. However, in Alzheimer’s disease, these proteins malfunction and aggregate into long, twisted fibrils. As these fibrils build up, they form neurofibrillary tangles- masses of tangled tau proteins
Read 15 tweets
Chise Profile picture
Oct 9, 2024
THIS IS HUGE! Researchers at the University of Pennsylvania have developed a vaccine against the bacterium Clostridioides difficile (C.diff), that in preclinical studies, protected against succumbing from infection AND prevented recurring cases. Let’s talk about that! 🧵⬇️
The study has been published in Science. Yes, it is PEER-REVIEWED.
• science.org/doi/10.1126/sc…Model figure. (A) C. difficile toxins target the intestinal epithelium and cause severe pathology and gastrointestinal disease leading to morbidity and mortality. (B) When vaccinated mice are infected with C. difficile, anti-toxin IgG and IgA protect mice from disease and inclusion of PPEP-1 and CdeM as immunogens improves decolonization of toxigenic C. difficile from the gastrointestinal tract. Credit: Science (2024). DOI: 10.1126/science.adn4955
The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a million people in the U.S. contract C. diff every year, often from hospitals-
Read 15 tweets
Chise Profile picture
Oct 5, 2024
THIS IS HUGE! Scientists at the University of Oxford are developing the world's FIRST ovarian cancer vaccine that could potentially wipe the disease out. OvarianVax teaches the immune system to recognize and attack the earliest stages of ovarian cancer. Let’s talk about that!🧵⬇️
The hope is that individuals could receive the vaccine preventatively with the goal of eradicating the disease. Researchers have suggested it could work in a similar way to the human papillomavirus (HPV) vaccine, which is on track to stamp out cervical cancer.
Oxford researchers are designing OvarianVax, a vaccine which teaches the immune system to recognize and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(